ANDROGENETIC ALOPECIA (AGA)
Clinical trials for ANDROGENETIC ALOPECIA (AGA) explained in plain language.
Never miss a new study
Get alerted when new ANDROGENETIC ALOPECIA (AGA) trials appear
Sign up with your email to follow new studies for ANDROGENETIC ALOPECIA (AGA), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a friendly bacteria lotion help regrow hair?
Disease control Recruiting nowThis study tests whether applying a lotion containing live Lactobacillus reuteri bacteria to the scalp can safely improve hair growth in people with male or female pattern baldness. About 388 adults aged 18-60 will use either the probiotic lotion, a placebo, or standard minoxidil…
Matched conditions: ANDROGENETIC ALOPECIA (AGA)
Phase: PHASE2 • Sponsor: Shenzhen People's Hospital • Aim: Disease control
Last updated Apr 30, 2026 15:49 UTC
-
New hair loss drug enters human trials
Disease control Recruiting nowThis study tests a new drug called OLX72021 in healthy men with mild to moderate male pattern baldness. The goal is to see if it is safe and can help regrow hair. Participants receive multiple injections into the scalp and are monitored for side effects and hair count changes ove…
Matched conditions: ANDROGENETIC ALOPECIA (AGA)
Phase: PHASE1, PHASE2 • Sponsor: Olix Pharmaceuticals, Inc. • Aim: Disease control
Last updated Apr 29, 2026 15:14 UTC
-
Botox and platelets join forces in new hair loss trial
Disease control Recruiting nowThis study tests whether combining platelet-rich plasma (PRP) with Botox injections works better than PRP alone for treating androgenetic alopecia (common baldness). About 76 adults aged 18 to 60 with mild to moderate hair loss will receive three monthly scalp injections. The goa…
Matched conditions: ANDROGENETIC ALOPECIA (AGA)
Phase: PHASE2 • Sponsor: Nanfang Hospital, Southern Medical University • Aim: Disease control
Last updated Apr 29, 2026 15:03 UTC
-
New pill could help women regrow hair – major trial underway
Disease control Recruiting nowThis study tests an experimental oral drug called VDPHL01 for women with mild to moderate genetic hair loss (androgenetic alopecia). About 552 women aged 18–65 will receive either the drug or a placebo for 13 months. The main goal is to see if the drug increases hair count and is…
Matched conditions: ANDROGENETIC ALOPECIA (AGA)
Phase: PHASE3 • Sponsor: Veradermics, Inc. • Aim: Disease control
Last updated Apr 29, 2026 15:02 UTC